ReviewFrontiers in pharmacology2025
Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Network Pharmacology and Experimental Validation Elucidate the Anti-Angiogenic Mechanism of Silibinin.Chemistry & biodiversity · 2026Article
- Silymarin attenuates diabetic nephropathy in rats via modulation of the miRNA-223/NLRP3/caspase-1/GSDMD axis and inflammasome-related pyroptotic signaling.Biology direct · 2026Article
- Efficacy and Mechanism of Silymarin Extract for Deep Second-Degree Burns in Rats.Chinese journal of integrative medicine · 2026Article
- Subchronic Cadmium-Induced Xenobiotic Toxicity in Male Wistar Rats: Antioxidant and Reproductive Protection by Standardized Silymarin with Molecular Docking Insights.Journal of xenobiotics · 2026Article
- Review
- Ameliorative Role of Silymarin in Methotrexate-Induced Pulmonary Damage: A Multi-Pathway Molecular Approach.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silymarin, extracted from the seeds of Silybum marianum (milk thistle), has been utilised in traditional medicine for many years and is recognised for its neuroprotective and hepatoprotective properties. Existing research reveals that silymarin has potent antioxidant and anti-inflammatory effects, coupled with anti-fibrotic, anti-carcinogenic, neuro-regenerative, and immunomodulatory actions, and has broad therapeutic relevance in both neurological and hepatic disorders, albeit with the drawback of low solubility. Silymarin participates in multiple molecular and cellular pathways to show its therapeutic effect. Nanocarriers are a promising solution to silymarin's low solubility and limited bioavailability, aiming to enhance targeted delivery to the central nervous system and hepatic tissue. These developments position silymarin as a multi-domain phytopharmaceutical with significant translational potential. This review provides an overview of silymarin's historical context, phytochemical composition, and pharmacokinetic profile, with a particular focus on targeted drug delivery systems. Special emphasis is placed on its potential role in managing various diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.